Dechra Pharmaceuticals PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DPHAY research report →
Companywww.dechra.com
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
- CEO
- Ian D. Page
- IPO
- 2018
- Employees
- 2,457
- HQ
- Northwich, GB
Price Chart
Valuation
- Market Cap
- $5.58B
- P/E
- -157.24
- P/S
- 5.78
- P/B
- 5.81
- EV/EBITDA
- 55.75
- Div Yield
- 0.32%
Profitability
- Gross Margin
- 55.98%
- Op Margin
- 0.83%
- Net Margin
- -3.66%
- ROE
- -3.92%
- ROIC
- 0.35%
Growth & Income
- Revenue
- $761.50M · 11.69%
- Net Income
- $-27,900,000 · -147.94%
- EPS
- $-0.24 · -144.44%
- Op Income
- $6.30M
- FCF YoY
- -26.49%
Performance & Tape
- 52W High
- $98.00
- 52W Low
- $61.61
- 50D MA
- $94.61
- 200D MA
- $93.00
- Beta
- 0.75
- Avg Volume
- 3
Get TickerSpark's AI analysis on DPHAY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DPHAY Coverage
We haven't published any research on DPHAY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DPHAY Report →